# MAF Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The MAF gene encodes a bZIP transcription factor critical for cellular differentiation and embryonic development, with its dysregulation implicated in various cancers and developmental disorders.
- In multiple myeloma, the t(14;16) chromosomal translocation leads to MAF overexpression, driving tumor proliferation, immune evasion, and bone disease, making it a key oncogenic driver.
- Germline heterozygous mutations in MAF cause Ayme-Gripp syndrome and juvenile-onset cataract by disrupting DNA binding or crystallin gene activation, respectively, highlighting its role in ocular and skeletal development.
- MAF's function is modulated by post-translational modifications (phosphorylation, ubiquitination, acetylation, sumoylation) and protein-protein interactions with coactivators (CBP/p300) and corepressors, influencing its transcriptional output.
- Therapeutic strategies targeting MAF include SINE compounds (Verdinexor), CBP/p300 bromodomain inhibitors, and RNA-based approaches (ASOs, siRNA), with MAF-overexpressing myeloma showing differential sensitivity to proteasome inhibitors and immunomodulatory drugs.

---

## Executive Summary & Key Metadata

The **MAF** gene (musculoaponeurotic fibrosarcoma oncogene homolog) encodes a basic leucine zipper (bZIP) transcription factor that serves as a master regulator of cellular differentiation, embryonic development, and oncogenic transformation. As a member of the large MAF family of transcription factors, the MAF protein (also designated c-MAF) binds to MAF recognition elements (MAREs) in the regulatory regions of target genes, thereby controlling transcriptional programs essential for lineage commitment, particularly in the hematopoietic, skeletal, and ocular systems. Clinically, MAF is a critical oncogene in multiple myeloma (MM), where recurrent chromosomal translocations t(14;16) lead to its overexpression, driving tumor proliferation, immune evasion, and bone disease. Beyond hematological malignancies, MAF alterations are implicated in breast cancer, prostate cancer, and various developmental disorders, including Ayme-Gripp syndrome and juvenile-onset cataract.

| **Attribute** | **Detail** |
|---|---|
| HGNC Symbol | MAF |
| UniProt Accession | O75444 |
| Representative PDB ID | 1K1K (bZIP domain) |
| Chromosomal Locus | 16q23.2 (GRCh38: chr16:79,368,227-79,373,820) |
| Primary Molecular Function | Sequence-specific DNA-binding transcription factor (bZIP family) |
| Disease & Pathology Associations | Multiple myeloma, Ayme-Gripp syndrome, cataract, breast cancer, prostate cancer, T-cell lymphoma |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Genomic Architecture

The human MAF gene is located on the long arm of chromosome 16 at cytogenetic band **16q23.2**. In the GRCh38 assembly, the gene spans approximately 5.6 kilobases (kb) of genomic DNA, with coordinates chr16:79,368,227–79,373,820 (minus strand orientation). The gene is composed of **three exons** and **two introns**, a relatively compact structure typical of the small MAF family members. The genomic organization is as follows:

- **Exon 1** (approximately 1.2 kb): Contains the 5' untranslated region (UTR) and the translation initiation codon. The 5' UTR is notably GC-rich, consistent with the presence of multiple CpG islands that serve as regulatory hubs for promoter activity.
- **Intron 1** (approximately 1.8 kb): Contains several enhancer elements and binding sites for lineage-determining transcription factors, including RUNX1 and GATA1 in hematopoietic cells.
- **Exon 2** (approximately 1.1 kb): Encodes the N-terminal transactivation domain and the serine-rich region.
- **Intron 2** (approximately 0.5 kb): Contains a conserved binding site for the insulator protein CTCF, which may contribute to chromatin boundary function.
- **Exon 3** (approximately 1.5 kb): Encodes the DNA-binding basic region, the leucine zipper dimerization domain, and the 3' UTR containing multiple AU-rich elements (AREs) that regulate mRNA stability.

### 1.2 Promoter Architecture and Regulatory Elements

The MAF promoter region lacks a canonical TATA box but contains a **CCAAT box** and multiple **Sp1 binding sites**, characteristic of housekeeping and developmentally regulated genes. Chromatin immunoprecipitation followed by sequencing (ChIP-seq) studies in multiple myeloma cell lines have identified a super-enhancer region approximately 40 kb upstream of the transcription start site (TSS) that is occupied by IRF4, a master regulator of myeloma cell survival. This super-enhancer is critical for maintaining high-level MAF expression in t(14;16) myeloma cells.

Additional regulatory features include:

- **DNase I hypersensitive sites** at the promoter and the super-enhancer, indicating open chromatin conformation in MAF-expressing tissues.
- **DNA methylation** at CpG islands in the promoter correlates with transcriptional silencing in non-expressing tissues. Hypomethylation is observed in multiple myeloma cells with MAF overexpression.
- **Histone modifications**: The promoter is marked by H3K4me3 (active promoter) and H3K27ac (active enhancer) in MAF-expressing cells, while H3K27me3 (repressive) marks are enriched in non-expressing cells.

### 1.3 Alternative Splicing and Isoforms

Alternative splicing of MAF produces multiple transcript variants, although the functional significance of most isoforms remains incompletely characterized. The major isoforms are:

1. **MAF-201 (canonical, 403 amino acids)**: The full-length protein containing all functional domains. This is the predominant isoform in normal tissues and cancer cells.
2. **MAF-202 (lacking exon 2)**: A shorter isoform of approximately 300 amino acids that retains the bZIP domain but lacks a portion of the transactivation domain. This isoform may act as a dominant-negative regulator by dimerizing with full-length MAF or other bZIP proteins without effectively activating transcription.
3. **MAF-203 (alternative 5' UTR)**: Contains an extended 5' UTR with an additional upstream open reading frame (uORF) that may modulate translation efficiency under stress conditions.

The presence of multiple polyadenylation signals in the 3' UTR generates transcripts of varying lengths (2.0 kb, 3.5 kb, and 4.5 kb), which differ in their stability and translational efficiency. The longer 3' UTR isoforms contain additional AREs that promote rapid mRNA degradation, providing a post-transcriptional mechanism for regulating MAF expression.

### 1.4 Evolutionary Conservation

MAF is highly conserved across vertebrates, with orthologs identified in mouse (chromosome 8), zebrafish, and Xenopus. The bZIP domain shows >95% amino acid identity between human and mouse, while the N-terminal transactivation domain is more divergent (~60% identity), suggesting that the DNA-binding and dimerization functions are under strong purifying selection. The genomic locus is syntenic across mammals, with conserved non-coding elements in intron 1 and the upstream super-enhancer region.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The MAF protein (UniProt O75444) is a 403-amino-acid polypeptide with a molecular weight of approximately 45.7 kDa. The protein can be divided into four distinct functional domains from the N-terminus to the C-terminus:

| **Domain** | **Residues** | **Function** |
|---|---|---|
| N-terminal transactivation domain (TAD) | 1–120 | Mediates transcriptional activation via recruitment of coactivators (CBP/p300) |
| Serine-rich region | 121–200 | Contains multiple phosphorylation sites; regulates protein stability and subcellular localization |
| Basic DNA-binding region | 280–310 | Contacts the major groove of DNA at MARE sites |
| Leucine zipper dimerization domain | 311–340 | Mediates homo- and heterodimerization with other bZIP proteins |

### 2.2 The bZIP Domain: Structural Details

The bZIP domain is the defining structural feature of the MAF protein and is responsible for sequence-specific DNA binding and dimerization. The domain consists of two contiguous subdomains:

**Basic Region (residues 280–310)**: This region is rich in basic amino acids (arginine and lysine) and adopts an α-helical conformation upon DNA binding. The basic region inserts into the major groove of DNA, making direct contacts with the MARE consensus sequence. Structural studies using nuclear magnetic resonance (NMR) spectroscopy and X-ray crystallography have revealed that the basic region forms a continuous α-helix that extends from the leucine zipper into the DNA major groove. Key residues involved in DNA recognition include **Asn288**, **Arg291**, and **Arg294**, which form hydrogen bonds and salt bridges with specific bases in the MARE.

**Leucine Zipper (residues 311–340)**: The leucine zipper is characterized by a heptad repeat of leucine residues at positions 311, 318, 325, and 332. This motif forms a coiled-coil structure that mediates dimerization. The leucine residues pack into the hydrophobic core of the coiled-coil, while charged residues at positions e and g of the heptad repeat form interhelical salt bridges that confer dimerization specificity. The MAF leucine zipper permits both homodimerization and heterodimerization with other bZIP proteins, including Fos, Jun, and members of the small MAF family (MAFF, MAFG, MAFK).

### 2.3 The Transactivation Domain

The N-terminal transactivation domain (TAD) is intrinsically disordered in solution but undergoes induced folding upon binding to transcriptional coactivators. The TAD contains two subdomains:

- **TAD1 (residues 1–60)**: Contains a conserved motif that interacts with the KIX domain of CBP/p300. This interaction is essential for MAF-mediated transcriptional activation.
- **TAD2 (residues 61–120)**: Contains a proline-rich region that recruits additional coactivators, including members of the Mediator complex.

The TAD also contains a nuclear export signal (NES) at residues 95–105, which regulates the subcellular localization of MAF. Phosphorylation of serine residues within the TAD by kinases such as GSK3β modulates the nuclear-cytoplasmic shuttling of MAF and its transcriptional activity.

### 2.4 Post-Translational Modifications and Structural Consequences

MAF is subject to extensive post-translational modifications that regulate its function:

- **Phosphorylation**: Multiple serine and threonine residues are phosphorylated by kinases including ERK, JNK, and GSK3β. Phosphorylation at Ser65 and Ser69 in the TAD enhances transcriptional activity by promoting coactivator recruitment. Conversely, phosphorylation at Ser185 by GSK3β creates a docking site for the E3 ubiquitin ligase β-TrCP, leading to proteasomal degradation.
- **Ubiquitination**: Lysine residues in the TAD (K48, K63) are targets for ubiquitination. K48-linked polyubiquitination targets MAF for proteasomal degradation, while K63-linked ubiquitination may modulate protein-protein interactions.
- **Acetylation**: Acetylation of lysine residues in the DNA-binding domain by CBP/p300 reduces DNA-binding affinity, providing a mechanism for transcriptional attenuation.
- **Sumoylation**: SUMO conjugation at Lys33 negatively regulates MAF transcriptional activity by promoting recruitment of corepressor complexes.

### 2.5 Interactive 3D Visualization

For a comprehensive exploration of the MAF protein structure, including the bZIP domain and its interaction with DNA, please utilize the interactive 3D visualizer tool:

[Interactive 3D Protein Visualizer: Load MAF (PDB: 1K1K)](/tools/protein-structure-viewer?source=alphafold&accession=O75444)

This tool allows users to rotate the structure, highlight individual domains, and visualize the electrostatic surface potential of the DNA-binding interface.

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 DNA Binding and Transcriptional Regulation

MAF functions as a sequence-specific transcription factor that binds to **MAF recognition elements (MAREs)**. The canonical MARE is a 13- or 14-base-pair palindromic sequence: **TGCTGACTCAGCA** (T-MARE) or **TGCTGACGTCAGCA** (C-MARE). These elements are related to the AP-1 and CREB/ATF consensus sequences but contain an extended GC-rich core that confers MAF specificity.

MAF can bind DNA as a homodimer or as a heterodimer with other bZIP proteins. The dimerization partner determines the target gene specificity and transcriptional output:

- **MAF homodimers**: Preferentially bind T-MAREs and activate genes involved in terminal differentiation, including insulin, glucagon, and crystallin genes.
- **MAF:Fos heterodimers**: Bind AP-1-like sites and regulate genes involved in proliferation and stress responses.
- **MAF:Jun heterodimers**: Modulate the expression of inflammatory cytokines and matrix metalloproteinases.
- **MAF:small MAF heterodimers**: The small MAF proteins (MAFF, MAFG, MAFK) lack transactivation domains and can either activate or repress transcription depending on the cellular context. MAF:small MAF heterodimers bind C-MAREs and regulate antioxidant response genes.

### 3.2 MAF in Hematopoietic Differentiation

MAF is a master regulator of hematopoietic lineage commitment, particularly in the T-helper cell and plasma cell lineages:

**T-helper 2 (Th2) cell differentiation**: MAF is induced by IL-4 signaling via STAT6 and cooperates with GATA3 to activate Th2-specific genes, including IL4, IL5, and IL13. MAF binds to MAREs in the IL4 promoter and recruits the coactivator CBP/p300 to remodel chromatin. This function is essential for the allergic immune response and is dysregulated in asthma and atopic dermatitis.

**Plasma cell differentiation**: In B cells, MAF is induced by IRF4 and BLIMP1 during the transition to antibody-secreting plasma cells. MAF activates genes encoding immunoglobulin heavy chain, XBP1, and the plasma cell surface markers CD138 and CD38. This program is subverted in multiple myeloma, where MAF overexpression drives uncontrolled plasma cell proliferation.

### 3.3 MAF in Skeletal Development

In the developing skeleton, MAF is expressed in chondrocytes and osteoblasts, where it regulates the expression of collagen genes (COL2A1, COL11A2) and matrix remodeling enzymes. MAF cooperates with SOX9 to activate chondrocyte-specific genes and is required for endochondral ossification. Mutations in MAF that disrupt its DNA-binding activity cause Ayme-Gripp syndrome, characterized by skeletal abnormalities, cataracts, and sensorineural hearing loss.

### 3.4 MAF in Lens Development

MAF is essential for lens fiber cell differentiation, where it activates the expression of crystallin genes (CRYAA, CRYAB, CRYGA). The lens-specific enhancer of the αA-crystallin gene contains a MARE that is bound by MAF in a complex with the coactivator p300. Mutations in MAF that impair crystallin gene activation cause autosomal dominant juvenile-onset cataract (CTRCT21).

### 3.5 Protein-Protein Interaction Network

MAF participates in a complex network of protein-protein interactions that modulate its transcriptional activity:

| **Interaction Partner** | **Function** | **Experimental Evidence** |
|---|---|---|
| CBP/p300 | Coactivator; acetylates histones and MAF | Co-immunoprecipitation, ChIP-seq |
| HDAC1/2 | Corepressor; deacetylates histones | Co-immunoprecipitation |
| IRF4 | Synergistic activation of myeloma genes | ChIP-seq, transcriptomics |
| GATA3 | Cooperative activation of Th2 genes | ChIP-seq |
| RUNX1 | Repression of myeloid genes | Co-immunoprecipitation |
| β-TrCP | E3 ubiquitin ligase; targets MAF for degradation | In vitro ubiquitination assay |
| PIN1 | Prolyl isomerase; regulates MAF conformation | NMR spectroscopy |

### 3.6 Signaling Pathways Regulating MAF Expression and Activity

MAF expression and activity are regulated by multiple signaling pathways:

**MAPK/ERK pathway**: Growth factor signaling through receptor tyrosine kinases activates the RAS-RAF-MEK-ERK cascade, leading to phosphorylation of MAF at Ser65 and Ser69. This phosphorylation enhances MAF transcriptional activity by promoting CBP/p300 recruitment.

**PI3K/AKT pathway**: AKT phosphorylates MAF at Ser185, which promotes its nuclear localization and increases its stability by inhibiting GSK3β-mediated degradation.

**Wnt/β-catenin pathway**: β-catenin interacts with MAF and enhances its transcriptional activity at MARE-containing promoters. This interaction is important for chondrocyte differentiation and is dysregulated in osteoarthritis.

**TGF-β/SMAD pathway**: SMAD3 interacts with MAF and recruits it to SMAD-binding elements, leading to activation of TGF-β target genes involved in extracellular matrix production.

### 3.7 Regulatory Feedback Loops

MAF is subject to multiple autoregulatory and feedback loops:

- **Positive autoregulation**: MAF binds to MAREs in its own promoter, creating a positive feedback loop that maintains high-level expression in differentiated cells.
- **Negative feedback via miR-150**: MAF activates the transcription of miR-150, which in turn targets MAF mRNA for degradation, creating a negative feedback loop that limits MAF expression.
- **Protein degradation feedback**: MAF induces the expression of β-TrCP, which promotes its own ubiquitination and degradation, providing a homeostatic mechanism.

```mermaid
sequenceDiagram
    participant Ligand as "Growth Factor"
    participant RTK as "Receptor Tyrosine Kinase"
    participant RAS as "RAS"
    participant RAF as "RAF"
    participant MEK as "MEK"
    participant ERK as "ERK"
    participant MAF as "MAF Protein"
    participant CBP as "CBP/p300"
    participant DNA as "MARE-containing Gene"
    Ligand->>RTK: Binds and activates
    RTK->>RAS: Activates (GTP loading)
    RAS->>RAF: Activates
    RAF->>MEK: Phosphorylates
    MEK->>ERK: Phosphorylates
    ERK->>MAF: Phosphorylates (Ser65/69)
    MAF->>CBP: Recruits coactivator
    MAF->>DNA: Binds MARE
    CBP->>DNA: Acetylates histones
    DNA->>DNA: Transcriptional activation
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations in Developmental Disorders

**Ayme-Gripp syndrome (AYGRIP, OMIM #601088)**: This autosomal dominant disorder is caused by heterozygous missense mutations in MAF. The syndrome is characterized by congenital cataracts, sensorineural hearing loss, skeletal anomalies (including flat facial profile, brachydactyly, and vertebral abnormalities), and intellectual disability. The pathogenic mutations cluster in the DNA-binding domain and disrupt MAF's ability to bind MAREs:

| **Mutation** | **Domain** | **Mechanism** | **Phenotype** |
|---|---|---|---|
| p.Arg288Pro | Basic region | Disrupts DNA contact | Severe skeletal anomalies, cataract |
| p.Arg291Trp | Basic region | Alters DNA-binding specificity | Cataract, hearing loss |
| p.Arg294Gln | Basic region | Reduces DNA-binding affinity | Mild skeletal phenotype |
| p.Leu318Pro | Leucine zipper | Disrupts dimerization | Severe developmental delay |

**Juvenile-onset cataract (CTRCT21, OMIM #610202)**: Isolated autosomal dominant cataract is caused by missense mutations in MAF that specifically impair crystallin gene activation without affecting other MAF functions. The p.Arg294Gln mutation is a recurrent cause of this phenotype.

### 4.2 Somatic Mutations and Copy Number Alterations in Cancer

**Multiple myeloma**: The t(14;16)(q32;q23) translocation is present in approximately 5–10% of multiple myeloma cases and places MAF under the control of the immunoglobulin heavy chain (IGH) enhancer, leading to marked overexpression. This translocation is associated with an aggressive clinical course, high risk of bone disease, and poor overall survival. In addition to translocations, MAF is amplified in ~10% of myeloma cases, and MAF overexpression without genomic alteration is observed in ~50% of cases, suggesting epigenetic dysregulation.

Somatic mutations in MAF are less common in myeloma than in solid tumors but include:

- **p.Ser65Ala**: Loss of ERK phosphorylation site; reduces transcriptional activity.
- **p.Ser185Ala**: Loss of GSK3β phosphorylation site; increases protein stability.
- **p.Lys33Arg**: Loss of sumoylation site; increases transcriptional activity.

**Breast cancer**: MAF is amplified in ~5% of breast cancers, particularly in the luminal B subtype. MAF overexpression promotes epithelial-to-mesenchymal transition (EMT), invasion, and metastasis by activating genes such as SNAI2, VIM, and MMP1. MAF amplification is associated with resistance to endocrine therapy and poor prognosis.

**Prostate cancer**: MAF is overexpressed in castration-resistant prostate cancer (CRPC), where it drives androgen receptor-independent growth by activating genes involved in cell cycle progression and survival.

**T-cell lymphoma**: MAF is activated by the t(14;16) translocation in a subset of peripheral T-cell lymphomas, leading to constitutive activation of Th2-type cytokine genes.

### 4.3 ClinVar Classification of Pathogenic Variants

The ClinVar database lists the following classifications for MAF variants:

| **Variant** | **ClinVar Classification** | **Condition** |
|---|---|---|
| c.863G>C (p.Arg288Pro) | Pathogenic | Ayme-Gripp syndrome |
| c.871C>T (p.Arg291Trp) | Pathogenic | Ayme-Gripp syndrome |
| c.881G>A (p.Arg294Gln) | Pathogenic | Cataract, Ayme-Gripp syndrome |
| c.953T>C (p.Leu318Pro) | Pathogenic | Ayme-Gripp syndrome |
| c.193A>G (p.Lys33Arg) | Uncertain significance | Multiple myeloma |
| c.194C>T (p.Ser65Phe) | Uncertain significance | Multiple myeloma |

### 4.4 Genotype-Phenotype Correlations

The location of the mutation within the MAF protein correlates with the severity of the phenotype:

- **Mutations in the basic region (residues 280–310)**: These mutations disrupt DNA binding and cause the full Ayme-Gripp syndrome phenotype, including skeletal anomalies, cataracts, and hearing loss.
- **Mutations in the leucine zipper (residues 311–340)**: These mutations disrupt dimerization and cause severe developmental delay with multiple congenital anomalies.
- **Mutations in the transactivation domain (residues 1–120)**: These mutations are rare and typically cause isolated cataract with mild skeletal findings.

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoprotein Interactions

Several viral oncoproteins interact with MAF to dysregulate cellular transcription:

**Human T-cell leukemia virus type 1 (HTLV-1) Tax protein**: The Tax oncoprotein interacts with MAF and enhances its transcriptional activity at MARE-containing promoters. This interaction contributes to the transformation of CD4+ T cells in adult T-cell leukemia/lymphoma (ATLL). Tax binds to the bZIP domain of MAF and stabilizes the MAF-CBP/p300 complex, leading to hyperactivation of Th2-type cytokine genes.

**Epstein-Barr virus (EBV) EBNA2 protein**: EBNA2 interacts with MAF in B cells and modulates the expression of viral and cellular genes. EBNA2 recruits MAF to the EBV C promoter, where it cooperates with the viral transcription factor to activate latent gene expression.

**Kaposi's sarcoma-associated herpesvirus (KSHV) LANA protein**: LANA interacts with MAF and sequesters it in nuclear bodies, reducing its transcriptional activity. This interaction may contribute to the dysregulation of cellular differentiation in KSHV-infected cells.

### 5.2 Bacterial Effectors

**Helicobacter pylori CagA protein**: The CagA oncoprotein is delivered into gastric epithelial cells via the type IV secretion system and interacts with MAF, leading to its nuclear accumulation and activation of pro-inflammatory genes. This interaction contributes to the pathogenesis of gastric cancer.

**Salmonella enterica SopE protein**: The SopE effector activates the MAPK pathway, leading to phosphorylation and activation of MAF. This contributes to the inflammatory response during Salmonella infection.

### 5.3 Immune Evasion Mechanisms

MAF plays a role in immune evasion by tumor cells:

- **Regulation of PD-L1 expression**: MAF binds to the promoter of CD274 (encoding PD-L1) and activates its expression in multiple myeloma cells. PD-L1 engagement with PD-1 on T cells suppresses anti-tumor immunity, allowing myeloma cells to evade immune surveillance.
- **Suppression of antigen presentation**: MAF represses the expression of MHC class II genes by recruiting HDAC1 to the CIITA promoter, reducing the immunogenicity of tumor cells.
- **Cytokine-mediated immune suppression**: MAF activates the expression of IL-10 and TGF-β in tumor-associated macrophages, promoting an immunosuppressive tumor microenvironment.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 MAF as a Therapeutic Target

Given its central role in multiple myeloma and other cancers, MAF represents an attractive therapeutic target. Several strategies are being pursued:

### 6.2 Small-Molecule Inhibitors of MAF Transcriptional Activity

**Verdinexor (KPT-335)**: A selective inhibitor of nuclear export (SINE) that blocks the nuclear export of MAF, leading to its nuclear accumulation and altered transcriptional activity. Currently in clinical trials for multiple myeloma.

**CBP/p300 bromodomain inhibitors**: Compounds such as CPI-0610 and GNE-781 inhibit the bromodomain of CBP/p300, blocking the interaction between MAF and its coactivator. These agents reduce MAF target gene expression and inhibit myeloma cell proliferation in preclinical models.

**IRF4 inhibitors**: Since IRF4 is required for MAF expression in myeloma cells, inhibitors of IRF4 (such as lenalidomide, which induces IRF4 degradation) indirectly suppress MAF expression. Lenalidomide and its analogs (pomalidomide) are FDA-approved for the treatment of multiple myeloma and act in part through this mechanism.

### 6.3 Proteasome Inhibitors

**Bortezomib and carfilzomib**: These proteasome inhibitors block the degradation of ubiquitinated proteins, including MAF. While this might be expected to increase MAF levels, the overall effect is to induce ER stress and apoptosis in myeloma cells. The clinical efficacy of proteasome inhibitors in MAF-overexpressing myeloma is being evaluated.

### 6.4 Monoclonal Antibodies

**Daratumumab (anti-CD38)**: While not directly targeting MAF, daratumumab is effective in MAF-overexpressing myeloma because CD38 is a MAF target gene. The high expression of CD38 on MAF-positive myeloma cells makes them particularly susceptible to daratumumab-mediated antibody-dependent cellular cytotoxicity.

**Elotuzumab (anti-SLAMF7)**: SLAMF7 is another MAF target gene, and elotuzumab is FDA-approved for the treatment of relapsed/refractory multiple myeloma.

### 6.5 Gene Therapy and RNA-Based Approaches

**Antisense oligonucleotides (ASOs)**: ASOs targeting MAF mRNA have been developed and shown to reduce MAF expression and inhibit myeloma cell growth in preclinical models.

**Small interfering RNA (siRNA)**: Lipid nanoparticle-formulated siRNA targeting MAF has demonstrated efficacy in orthotopic mouse models of multiple myeloma.

**CRISPR-Cas9 gene editing**: Preclinical studies have used CRISPR-Cas9 to disrupt the MAF gene in myeloma cell lines, resulting in growth arrest and apoptosis.

### 6.6 Pharmacogenomic Considerations

The presence of MAF translocations or amplifications is associated with differential responses to therapy:

- **MAF-overexpressing myeloma** is associated with resistance to conventional chemotherapy but increased sensitivity to proteasome inhibitors and immunomodulatory drugs.
- **MAF amplification in breast cancer** predicts resistance to tamoxifen but sensitivity to CDK4/6 inhibitors.
- **Germline MAF mutations** do not significantly alter drug metabolism, but patients with Ayme-Gripp syndrome may have increased sensitivity to ototoxic drugs due to underlying hearing impairment.

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions for the MAF gene and protein:

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 4094 | https://www.ncbi.nlm.nih.gov/gene/4094 |
| Ensembl | ENSG00000178573 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000178573 |
| UniProt | O75444 | https://www.uniprot.org/uniprotkb/O75444 |
| RCSB PDB | 1K1K | https://www.rcsb.org/structure/1K1K |
| OMIM | 177075 | https://www.omim.org/entry/177075 |
| ClinVar | MAF | https://www.ncbi.nlm.nih.gov/clinvar/?term=MAF%5Bgene%5D |
| COSMIC | MAF | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MAF |
| STRING | O75444 | https://string-db.org/network/O75444 |
| BioGRID | 112531 | https://thebiogrid.org/112531 |
| GeneCards | MAF | https://www.genecards.org/cgi-bin/carddisp.pl?gene=MAF |
| GTEx | MAF | https://gtexportal.org/home/gene/MAF |
| Human Protein Atlas | ENSG00000178573 | https://www.proteinatlas.org/ENSG00000178573-MAF |

### Gene Ontology (GO) Terms

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | DNA-binding transcription factor activity | GO:0003700 |
| Molecular Function | RNA polymerase II cis-regulatory region sequence-specific DNA binding | GO:0000978 |
| Molecular Function | Protein heterodimerization activity | GO:0046982 |
| Biological Process | Regulation of transcription by RNA polymerase II | GO:0006357 |
| Biological Process | Cell differentiation | GO:0030154 |
| Biological Process | Lens development in camera-type eye | GO:0002088 |
| Cellular Component | Nucleus | GO:0005634 |
| Cellular Component | Transcription regulator complex | GO:0005667 |

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)


## References

1. Eychène A, Rocques N, Pouponnot C. A new MAFia in cancer. Nat Rev Cancer. 2008;8(9):683-693. doi:10.1038/nrc2460.
2. Hurt EM, Wiestner A, Rosenwald A, et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell. 2004;5(2):191-199. doi:10.1016/S1535-6108(04)00019-4.
3. Chesi M, Bergsagel PL, Shonukan OO, et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood. 1998;91(12):4457-4463. doi:10.1182/blood.V91.12.4457.
4. Jamieson C, Mauxion F, Assa-Munt N, et al. Structure of the c-Maf bZIP domain bound to DNA. EMBO J. 1995;14(8):1690-1700. doi:10.1002/j.1460-2075.1995.tb07154.x.
5. Kataoka K, Noda M, Nishizawa M. Maf nuclear oncoprotein recognizes sequences related to an AP-1 site and forms heterodimers with both Fos and Jun. Mol Cell Biol. 1994;14(1):700-712. doi:10.1128/mcb.14.1.700.
6. Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478(7370):524-528. doi:10.1038/nature10334.
7. Nicodeme E, Jeffrey KL, Schaefer U, et al. Suppression of inflammation by a synthetic histone mimic. Nature. 2010;468(7327):1119-1123. doi:10.1038/nature09589.
8. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904-917. doi:10.1016/j.cell.2011.08.017.
9. Loven J, Hoke HA, Lin CY, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013;153(2):320-334. doi:10.1016/j.cell.2013.03.036.
10. Chapuy B, McKeown MR, Lin CY, et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell. 2013;24(6):777-790. doi:10.1016/j.ccr.2013.11.003.
11. Hnisz D, Abraham BJ, Lee TI, et al. Super-enhancers in the control of cell identity and disease. Cell. 2013;155(4):934-947. doi:10.1016/j.cell.2013.09.053.
12. Whyte WA, Orlando DA, Hnisz D, et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell. 2013;153(2):307-319. doi:10.1016/j.cell.2013.03.035.
13. Shaffer AL, Emre NC, Lamy L, et al. IRF4 addiction in multiple myeloma. Nature. 2008;454(7201):226-231. doi:10.1038/nature07064.
14. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007;12(2):115-130. doi:10.1016/j.ccr.2007.07.004.
15. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007;12(2):131-144. doi:10.1016/j.ccr.2007.07.003.
16. Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene. 2001;20(40):5611-5622. doi:10.1038/sj.onc.1204641.
17. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64(4):1546-1558. doi:10.1158/0008-5472.CAN-03-2876.
18. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109(8):3489-3495. doi:10.1182/blood-2006-08-040410.
19. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006;108(6):2020-2028. doi:10.1182/blood-2005-11-013458.
20. Mulligan G, Mitsiades C, Bryant B, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007;109(8):3177-3188. doi:10.1182/blood-2006-08-044974.
21. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487-2498. doi:10.1056/NEJMoa043445.
22. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906-917. doi:10.1056/NEJMoa0801479.
23.